Ann: Botanix Commercial Day Webinar Presentation, page-102

TLX is sitting at approx 8 times revenue as a good gauge for 1 FDA approved drug with another 2 to be approved late this year and next year, but from the pipeline i tend to think this is significantly undervalued. But i tend to agree that the average is usually 10-15 times revenue once the company becomes income producing.

So $300m revenue = $3B market cap or 6 x current shareprice, for 1% of the market. Remember BOT will have the best medication for a relativly unmet need which has no competition anywhere near as effective, amd the estimates are for 1% of the market for 6x current shareprice! Half the dermatologists prescribing for this condition said they would move their patients onto Sofdra, so the market share will be well over 1%.

So the chance of 10% of the market cannot be viewed as unachievable by any stretch, so 6x current shareprice for 1% of market means 60x shareprice for 10%. Now we are looking at gains unimaginable, but they have occured on the ASX before, so good luck all and I certainly hope the marketing for Sofdra can bring this drug into the market next month full force.